Under Greg Abel, Apple Stock Stays Put in Berkshire Portfolio
Berkshire Hathaway's latest moves under Greg Abel show a shift toward stability with Apple while betting bigger on Al...
This article outlines scenarios where target date funds may be preferable to index funds in a 401(k), focusing on simplicity and risk management.
26,105 articlesBerkshire Hathaway's latest moves under Greg Abel show a shift toward stability with Apple while betting bigger on Al...
Fox faced a sharp weekly decline as it moved to acquire Roku. This article breaks down the catalysts, financing, and ...
PSEG's steady, regulated core supports its payout, but 2025 earnings hinge on rate cases, fuel costs, and clean energ...
If you’re seeking reliable income in a choppy market, dividend energy stocks right now offer cash flow through infras...
GameStop’s walking away from a massive pay package marks a dramatic pivot as the company uses its stock to press a bi...
A practical, investor-focused guide to vericel (vcel) 2025 earnings. Learn how revenue, margins, and milestones could...
Maze Therapeutics stock still faces mixed signals from the market: a strong rally after a March dip, paired with a no...
Private credit making investors nervous highlights how market risk, defaults, and liquidity affect BDCs. Yet Main Str...
February highlighted a split in space stocks: Iridium rose on stabilizing results, while Redwire and Spacemobile tumb...
As Zebra Technologies previews its Q1 2026 results, investors weigh hardware demand, software subscriptions, and marg...
Investors are rethinking AI exposure as OpenAI speeds up monetization and questions about platform risk surface. The ...
Regencell Bioscience sits in the high-risk, high-reward world of early-stage biotech. Before you consider investing, ...